Recent Updates
Recently added Catalysts

mRNA--04 vaccine 10μg

Phase 1

COVID-19 | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: May 28, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment114
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05972993A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy AdultsPHASE1 COMPLETED 114Aug 7, 2023Oct 14, 2024May 28, 20254 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Any Solicited Administration Site Events
Day 1 to Day 7

The solicited administration site events are pain, redness, swelling and lymphadenopathy (axillary swelling/ tenderness on the same side of the body as the site of injection). Any = occurrence of the event regardless of intensity grade.

Number of Participants With Any Solicited Systemic Events
Day 1 to Day 7

The solicited systemic events are fever, headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness), chills, abdominal pain, vomiting and diarrhea. Fever is defined as body temperature ≥38ºC; preferred location for measuring the temperature is oral. Any = occurrence of the event regardless of intensity grade.

Number of Participants With Any Unsolicited Adverse Events (AEs)
Day 1 to Day 30

An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs. Any = occurrence of the event regardless of intensity grade.

Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities
Day 1 to Day 15

The hematological and biochemical parameters included alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin, creatinine, direct bilirubin, basophils, eosinophils increase, erytrocytes, hemoglobin decrease, lymphocytes decrease, mean corpuscular hemoglobin, mean corpuscular volume, monocytes, neutrophils decrease, platelets decrease, white blood cells (WBC) increase. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Number of Participants With Any Medically Attended Adverse Events (MAAEs)
Day 1 to Day 31

A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional. Any = occurrence of the event regardless of intensity grade.

Number of Participants With Any Serious Adverse Events (SAEs)
Day 1 to Day 31

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. Any = occurrence of the event regardless of intensity grade.

Number of Participants With Any Adverse Events of Special Interest (AESIs)
Day 1 to Day 31

AESIs include potential immune-mediated diseases (pIMDs) which are autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology, myocarditis, and pericarditis, virologically confirmed COVID-19 cases, anaphylaxis, or severe hypersensitivity within 24 hours after study investigational product administration. Any = occurrence of the event regardless of intensity grade.

Secondary Endpoints
Number of Participants With Any MAAEs
Throughout the study period (Day 1 to Month 6)
Number of Participants With Any SAEs
Throughout the study period (Day 1 to Month 6)
Number of Participants With Any AESIs
Throughout the study period (Day 1 to Month 6)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Part A, Group 1: mRNA CR-04 10 µgEXPERIMENTALParticipants received mRNA 10 micrograms (µg) administered on Day 1.
Part A, Group 1: PlaceboPLACEBO_COMPARATORParticipants received placebo dose administered on Day 1.
Part A, Group 2: mRNA CR-04 30 µgEXPERIMENTALParticipants received placebo dose administered on Day 1.
Part A, Group 2: PlaceboPLACEBO_COMPARATORParticipants received placebo dose administered on Day 1.
Part A, Group 3: mRNA CR-04 100 µgEXPERIMENTALParticipants received mRNA 100 µg administered on Day 1
Part A, Group 3: PlaceboPLACEBO_COMPARATORParticipants received placebo dose administered on Day 1.
Part B: mRNA CR-04 3 µgEXPERIMENTALParticipants received mRNA 3 µg administered on Day 1.
Part B: mRNA CR-04 10 µgEXPERIMENTALParticipants received mRNA 10 µg administered on Day 1.
Part B: PlaceboPLACEBO_COMPARATORParticipants received placebo dose administered on Day 1.
Interventions
NameTypeDescription
mRNA-CR-04 vaccine 10μgBIOLOGICALmRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
mRNA-CR-04 vaccine 30μgBIOLOGICALmRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
mRNA-CR-04 vaccine 100μgBIOLOGICALmRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
PlaceboDRUGPlacebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
mRNA-CR-04 vaccine 3μgBIOLOGICALmRNA CR-04 vaccine, 3 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 49 Years
SexALL
Healthy VolunteersYes
Study Sites4

Inclusion Criteria: 1. Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure. 2. Participants, who in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary and stu...

Countries:United States
Unlock Eligibility Criteria